High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients

Annals of Oncology

Volumn 28, Issue 4, 2017, Pages 741-747

  Allenson, K ^a   Castillo, J ^a   San Lucas, F A ^a   Scelo, G ^b   Kim, D U ^a   Bernard, V ^a   Davis, G ^a   Kumar, T ^a   Katz, M ^a   Overman, M J ^a   Foretova, L ^c   Fabianova, E ^d   Holcatova, I ^e   Janout, V ^f,g   Meric Bernstam, F ^h   Gascoyne, P ⁱ   Wistuba, I ^a   Varadhachary, G ^a   Brennan, P ^b   Hanash, S ^a   Li, D ^a   Maitra, Anirban ^a   Alvarez, H ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^d Regional Authority of Public Health in Banska Bystrica   (Slovakia)

^e CHARLES UNIVERSITY   (Czech Republic)

^f PALACKÝ UNIVERSITY   (Czech Republic)

^g UNIVERSITY OF OSTRAVA   (Czech Republic)

^h Institute for Personalized Cancer Therapy   (United States)

ⁱ ContinuumDx ^*  (United States)

Author keywords

Circulating tumor DNA; Exosome; KRAS; Liquid biopsy; Pancreatic cancer

Indexed keywords

DNA; K RAS PROTEIN; KRAS PROTEIN, HUMAN; PROTEIN P21; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CELL FREE SYSTEM; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EXOSOME; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; KRAS GENE; LIQUID BIOPSY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; BLOOD; EARLY CANCER DIAGNOSIS; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MUTATION; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; AGED; BIOMARKERS, TUMOR; CARCINOMA, PANCREATIC DUCTAL; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; EARLY DETECTION OF CANCER; EXOSOMES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS P21(RAS); REAL-TIME POLYMERASE CHAIN REACTION;

EID: 85019060081     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx004     Document Type: Article

References (35)

1. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med 2014; 371: 1039-1049.
2. Yeo TP. Demographics, epidemiology, and inheritance of pancreatic ductal adenocarcinoma. Semin Oncol 2015; 42: 8-18.
3. Warner E. Clinical practice. Breast-cancer screening. N Engl J Med 2011; 365: 1025-1032.
4. Arteaga CL. Progress in breast cancer: overview. Clin Cancer Res 2013; 19: 6353-6359.
5. Lieberman DA. Clinical practice. Screening for colorectal cancer. N Engl J Med 2009; 361: 1179-1187.
6. Lee MS, Kopetz S. Current Future Approaches to target the epidermal growth factor receptor and its downstream signaling in metastatic colorectal cancer. Clin Colorectal Cancer 2015; 14: 203-218.
7. Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive nonsmall-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, openlabel, randomised, phase 3 study. Lancet Oncol 2011; 12: 735-742.
8. Smith RA, Manassaram-Baptiste D, Brooks D et al. Cancer screening in the United States, 2015: a review of current American cancer society guidelines and current issues in cancer screening. CA Cancer J Clin 2015; 65: 30-54.
9. Katz MH, Wang H, Fleming JB et al. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 2009; 16: 836-847.
10. Howlader N NA, Krapcho M, Miller D et al. (eds). SEER Cancer Statistics Review, 1975-2013. Bethesda, MD: National Cancer Institute 2016.
11. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7-30.
12. Chakraborty S, Baine MJ, Sasson AR, Batra SK. Current status of molecular markers for early detection of sporadic pancreatic cancer. Biochim Biophys Acta 2011; 1815: 44-64.
13. Vietsch EE, van Eijck CH, Wellstein A. Circulating DNA and micro-RNA in patients with pancreatic cancer. Pancreat Disord Ther 2015; 5(2): 156.
14. Mulcahy HE, Lyautey J, Lederrey C et al. A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. Clin Cancer Res 1998; 4: 271-275.
15. Dianxu F, Shengdao Z, Tianquan H et al. A prospective study of detection of pancreatic carcinoma by combined plasma K-ras mutations and serum CA19-9 analysis. Pancreas 2002; 25: 336-341.
16. Maire F, Micard S, Hammel P et al. Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA. Br J Cancer 2002; 87: 551-554.
17. Uemura T, Hibi K, Kaneko T et al. Detection of K-ras mutations in the plasma DNA of pancreatic cancer patients. J Gastroenterol 2004; 39: 56-60.
18. Dabritz J, Preston R, Hanfler J, Oettle H. Follow-up study of K-ras mutations in the plasma of patients with pancreatic cancer: correlation with clinical features and carbohydrate antigen 19-9. Pancreas 2009; 38: 534-541.
19. Chen H, Tu H, Meng ZQ et al. K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer. Eur J Surg Oncol 2010; 36: 657-662.
20. Castells A, Puig P, Mora J et al. K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. J Clin Oncol 1999; 17: 578-584.
21. Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014; 32: 579-586.
22. Bettegowda C, Sausen M, Leary RJ et al. Detection of circulating tumor DNA in early-and late-stage human malignancies. Sci Transl Med 2014; 6: 224ra224.
23. Lu L, Risch HA. Exosomes: potential for early detection in pancreatic cancer. Future Oncol 2016; 12: 1081-1090.
24. Melo SA, Luecke LB, Kahlert C et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 2015; 523: 177-182.
25. San Lucas FA, Allenson K, Bernard V et al. Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes. Ann Oncol 2016; 27: 635-641.
26. Sluijter JP, Verhage V, Deddens JC et al. Microvesicles and exosomes for intracardiac communication. Cardiovasc Res 2014; 102: 302-311.
27. Skog J, Wurdinger T, van Rijn S et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008; 10: 1470-1476.
28. Demory Beckler M, Higginbotham JN, Franklin JL et al. Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS.Mol Cell Proteomics 2013; 12: 343-355.
29. Dictionaries NCI. U.S. Department of Health and Human Services. National Institutes of Health. National Cancer Institute 2015.
30. Kahlert C, Melo SA, Protopopov A et al. Identification of doublestranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. J Biol Chem 2014; 289: 3869-3875.
31. Jahr S, Hentze H, Englisch S et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001; 61: 1659-1665.
32. Diamandis EP. A word of caution on new and revolutionary diagnostic tests. Cancer Cell 2016; 29: 141-142.
33. Krimmel JD, SchmittMW, HarrellMI et al. Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues. Proc Natl Acad Sci USA 2016; 113: 6005-6010.
34. Poruk KE, Gay DZ, Brown K et al. The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med 2013; 13: 340-351.
35. Katz MH, Pisters PW, Evans DB et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 2008; 206: 833-846. Discussion 846-838.